Efficacy of GLP-1 receptor agonists on weight loss, BMI, and waist circumference for patients with obesity or overweight: a systematic review, meta-analysis, and meta-regression of 47 randomized controlled trials
Other studies have suggested that there is no significant difference in the risk of acute pancreatitis or pancreatic cancer between the two groups when GLP-1RA is used (84, 85)
Each group benefits from transparent math that translates milligrams into practical syringe volumes
While these outcomes are impressive, it is important to remember that clinical trial averages do not guarantee individual results
It produces 15 to 17 percent body weight loss
Retatrutide is an investigational once-weekly triple agonist that simultaneously activates GLP-1, GIP, and glucagon receptors, distinguishing it from approved agents such as semaglutide and tirzepatide